EUVIMEDEUVIMED entdecken
Open Access

Kappa opioid receptor availability predicts severity of anhedonia in schizophrenia

Mark Slifstein, Wenchao Qu, Roberto Gil, Jodi J Weinstein iD, Greg Perlman iD, Thomas Jaworski-Calara, Jiayan Meng, Bao Hu, Scott J Moeller iD, Guillermo Horga, Anissa Abi-Dargham

Neuropsychopharmacology · 2024

DOI: 10.1038/s41386-024-01975-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuropsychopharmacology, 2024. Verfasst von Mark Slifstein und 10 weiteren Autor:innen. Beteiligte Einrichtung: Renaissance School of Medicine, Stony Brook University, Stony Brook, New York, USA. mark.slifstein@stonybrookmedicine.edu. Hauptthemen laut MEDLINE: Receptors, Opioid, kappa, Anhedonia, Positron-Emission Tomography, Schizophrenia. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH), NIMH NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The kappa opioid receptor (KOR) and its endogenous agonist dynorphin have been implicated in multiple psychiatric conditions including psychotic disorders. We tested the hypotheses that kappa expression is elevated and associated with psychotic symptoms in schizophrenia. We measured kappa expression in unmedicated patients with schizophrenia (7 female, 6 male) and matched controls (7 female, 6 male) with positron emission tomography (PET). We also acquired a measurement of cumulative dopamine activity over the life span in the same subjects using neuromelanin sensitive MRI. We hypothesized that neuromelanin accumulation would be higher in patients than controls and that in patients there would be a positive association between KOR availability and neuromelanin accumulation. Fourteen patients and thirteen controls were enrolled. Whole brain dynamic PET imaging data using the KOR selective tracer [18F]LY245998 were acquired. Distribution volume (VT) was measured with region of interest analysis in 14 brain regions. Neuromelanin accumulation in midbrain dopaminergic nuclei was assessed in the same subjects. Positive and negative symptoms were measured by a clinical psychologist. We did not observe group level differences in KOR expression, neuromelanin accumulation or relationships of these to positive symptoms. Unexpectedly, we did observe strong positive associations between KOR expression and symptoms of anhedonia in the patients (Pearson r > 0.7, uncorrected p < 0.01 in 8 cortical brain regions). We also observed moderate associations between KOR expression and neuromelanin levels in patients. In conclusion, we did not observe a relationship between kappa and symptoms of psychosis but the observed relationship to the negative symptom of anhedonia is in line with recent work testing kappa antagonism as a therapy for anhedonia in depression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Opioid, kappaAnhedoniaPositron-Emission TomographySchizophreniaMagnetic Resonance ImagingHumansMaleFemaleAdultMelaninsBrainMiddle AgedYoung Adult

Substanzen

Receptors, Opioid, kappaneuromelaninMelanins

Autor:innen und Institutionen

  • Renaissance School of Medicine, Stony Brook University, Stony Brook, New York, USA. mark.slifstein@stonybrookmedicine.edu.
  • Renaissance School of Medicine, Stony Brook University, Stony Brook, New York, USA.
  • Vagelos College of Physicians and Surgeons, Columbia University, Stony Brook, New York, USA.
  • New York State Psychiatric Institute, Stony Brook, New York, USA.

ORCID-Profile: Jodi J Weinstein, Greg Perlman, Scott J Moeller

Förderung

  • U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH)
  • NIMH NIH HHS

Zitieren

APA

Slifstein, M., Qu, W., Gil, R., Weinstein, J. J., Perlman, G., Jaworski-Calara, T., Meng, J., Hu, B., Moeller, S. J., Horga, G., & Abi-Dargham, A. (2024). Kappa opioid receptor availability predicts severity of anhedonia in schizophrenia. Neuropsychopharmacology. https://doi.org/10.1038/s41386-024-01975-3

Vancouver

Slifstein M, Qu W, Gil R, Weinstein JJ, Perlman G, Jaworski-Calara T, et al. Kappa opioid receptor availability predicts severity of anhedonia in schizophrenia. Neuropsychopharmacology. 2024. doi:10.1038/s41386-024-01975-3

BibTeX
@article{Slifstein2024,
  author = {Slifstein, Mark and Qu, Wenchao and Gil, Roberto and Weinstein, Jodi J and Perlman, Greg and Jaworski-Calara, Thomas and Meng, Jiayan and Hu, Bao and Moeller, Scott J and Horga, Guillermo and Abi-Dargham, Anissa},
  title = {Kappa opioid receptor availability predicts severity of anhedonia in schizophrenia},
  journal = {Neuropsychopharmacology},
  year = {2024},
  doi = {10.1038/s41386-024-01975-3}
}
Kostenlos starten →